The BN007 trial found that adding immunotherapy to radiation did not outperform temozolomide. Median progression-free survival was slightly lower, but these findings offer critical lessons for future glioblastoma research and immunotherapy innovation.

Watch the episode here

👉 Explore ongoing biomarker-based clinical trials at https://wetrials.com/brain-cancer/

📍 Subscribe for more patient-friendly guides on cancer research and clinical trials.